iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Stock Price Today
Key Stats
- $27.04BMarket Cap
- 48,204,104Volume
- Fixed IncomeSector
- $112.9152W High
- $101.8352W Low
- 123 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares iBoxx $ Inv Grade Corporate Bond ETF has traded between a low of $101.83 and a high of $112.91, highlighting its annual price range. Buy and sell iShares iBoxx $ Inv Grade Corporate Bond ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Most Recent News
One sizable IPO, one direct listing, and one SPAC debuted; Oura delays multibillion-dollar IPO.
This week saw the debut of one sizable IPO, one direct listing, and one SPAC, alongside initial filings from three small IPOs, one direct listing, and six SPACs. Notably, Oura postponed its planned multibillion-dollar IPO, marking a significant devel...
Municipal bonds and high-yield muni-bond funds sharply sold off, raising risks and tax concerns.
Municipal bonds experienced a significant selloff over the past month, with high-yield municipal bond closed-end funds (CEFs) yielding over 8% dropping even more sharply. The article highlights data on five top big-yield muni-bond CEFs, focusing part...
Arrowhead's plozasiran shows strong results to challenge Ionis in severe hypertriglyceridemia market
Arrowhead Pharmaceuticals is set to compete with Ionis in treating severe hypertriglyceridemia (sHTG) using plozasiran, which benefits from a $215 million priority review voucher enabling a faster market launch. Phase III trials SHASTA-3 and SHASTA-4...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.